In summary, these findings demonstrate that sorafenib activates FAK signaling, which promotes cholesterol biosynthesis, leading to activation of the SHH pathway effector GLI1 and ultimately inducing sorafenib resistance in HCC cells. Here, GLI1 is linked to hepatocellular carcinoma.